The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma
Glioma
About this trial
This is an interventional diagnostic trial for Glioma focused on measuring Glioma, PET, EGFR vIII, Multimodal neuronavigation, Molecular pathology, PET-CT, Neuronavigation
Eligibility Criteria
Inclusion Criteria:
- Clinical manifestations and imaging examination (CT, MRI, et al) are in accordance with high grade glioma
- No PET/CT scanning contraindications
- No MRI scanning contraindications
- Patients older than 18 years old
- ECOG score between 0 to 2
- Patients with sufficient bone marrow, kidney and liver function reserve.
- All patients gave written informed consent.
Exclusion Criteria:
- Patient who has received immune therapy, radiation therapy, chemotherapy, hormone drugs, biological products or other clinical trials within 14 days.
- Patient who has received EGFR monoclonal antibody therapy within 4 weeks.
- Patients who has not fully recovered form the past drug toxicity reaction (CTCAE in grade 2 or above).
- Patient who has received major surgery within 7 days.
- Patients with allergies to immunoglobulin.
- Breastfeeding women.
- pregnant women
- Patients with severe clinical condition.
- Inability to give informed consent
Sites / Locations
- Huashan hospital, Fudan universityRecruiting
Arms of the Study
Arm 1
Experimental
High Grade Glioma
We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806(1-2mCi), which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from the"hot-spot" on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies.